Trial Profile
Randomised phase II study comparing capecitabine with oral cyclophosphamide & capecitabine in patients with advanced breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2016
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CycloX-II
- 04 Mar 2013 Primary endpoint 'Objective-clinical-response-rate' has not been met.
- 04 Mar 2013 Status changed from recruiting to completed.
- 04 Oct 2006 Status change